Quantum Innovations raises almost 10 million euros for cardiac surgery

Marc Nemitz Marc Nemitz | 20.06.2024

Quantum Innovations has received PLN 41 million in a financing round led by Vinci IQ ASI and MedTech Holding. The company develops technologies for monitoring organs during surgery

Warsaw, June 20, 2024 - Polish medtech company Quantum Innovations has raised almost 10 million euros (PLN 41 million) in its second financing round. The team, led by Dr. Grzegorz Suwalski, has developed the world's first sensor technology for monitoring organs during operations and transplants. Their Heart Sense solution enables real-time ECG monitoring directly from the surface of a beating heart. In addition, the Heart Guard technology tracks tissue metabolism, even during phases in which the heart is immobilized for heart surgery. The capital raised in the current financing round, led by the Vinci IQ ASI fund with participation from MedTech Holding, will be used to build a dedicated production line, conduct regulatory and clinical studies, obtain certifications and enter key global markets.

The challenge of cardiac surgery

Cardiac surgery is undoubtedly one of the most dynamic fields of medical development and has produced a multitude of breakthroughs and innovations over the past century. This includes not only the first heart transplant, but also the introduction of heart valves, vascular sutures, coronary artery bypass grafting (CABG) and a range of minimally invasive procedures such as transcatheter aortic valve implantation (TAVI). Despite these advances, cardiovascular disease remains one of the two leading causes of death in industrialized countries. According to the latest World Heart Report 2023 1, over half a billion people worldwide suffer from cardiovascular disease, which is responsible for almost 20.5 million deaths, accounting for around 30% of all deaths. Worrying data is also presented in a recent study by iData Research 2 , which states that around 900,000 heart operations are performed in the US each year, with this figure expected to rise to 1.3 million by 2029.

The development of our own production line gives us the opportunity to quickly start producing sophisticated tools that can be used in more medical fields, which will further increase our market reach.

Przemysław Furdal, VP of Quality at Quantum Innovations

The development of medical technologies significantly increases the success rate of thoracic surgeries and reduces complications and mortality rates. Surgeries, especially those involving internal organs, require extreme precision and continuous monitoring. None of the currently available tools or devices offer such capabilities. The technology developed by Polish startup Quantum Innovations aims to close this gap. Obtaining new and previously inaccessible precise signals from the organs and body parts undergoing surgery pushes the boundaries of our knowledge. Overcoming these barriers opens up perspectives for improving medical procedures. Thus, Heart Sense technology makes it possible to examine the ECG of the operated heart, in any of its positions, from any of its walls, directly from its surface. Heart Guard technology, on the other hand, monitors the metabolic acidosis of the heart. Studies show that using this data can help heart teams overcome knowledge gaps and prevent dangerous complications and deaths in patients. - explains Dr. Grzegorz Suwalski, founder and CEO of Quantum Innovations.

Certifications

The funding round currently raised by the Quantum Innovations team will be used to develop and build a production line in a clean room environment and to complete the necessary certifications, including regulatory and human clinical trials, which will help bring the product to global markets. The value of almost all sectors of the medical device market is constantly growing. As a result, the amount of investment in technology development in this area is also constantly increasing. This leads to continuous improvements in patient outcomes, which is the main mission of Quantum Innovations. - comments Pawlos Mandzios, VP of Finance at Quantum Innovations.

The introduction of these solutions into medical standards has the potential to significantly reduce complications and perioperative mortality associated with cardiac surgery.

Piotr Woliński, President of Vinci S.A.

The PLN 41 million transaction was led by Vinci IQ ASI, a fund established by BGK and managed by Vinci S.A., with the participation of the company's existing investor, MedTech Holding. "We were convinced to invest mainly by the breakthrough product and technology as well as the hands-on experience of the team. The solutions proposed by QI address an unmet need in clinical practice during thoracic surgery. The introduction of these solutions into medical standards has the potential to significantly reduce complications and perioperative mortality associated with cardiac surgery. Investing in medical technologies such as QI fits perfectly with the Fund's mission to support sustainable development." - comments Piotr Woliński, President of Vinci S.A., which manages the Vinci IQ ASI Fund.


Like it? Please spread the word:


Newsletter

Startups, stories and stats from the German startup ecosystem straight to your inbox. Subscribe with 2 clicks. Noice.

LinkedIn Connect

Take care, give care

Did this news inform or entertain you? Then we would be happy if you tell your network about it.

Share on Linkedin Share on Facebook Share on Xing

FYI: English edition available

Hello my friend, have you been stranded on the German edition of Startbase? At least your browser tells us, that you do not speak German - so maybe you would like to switch to the English edition instead?

Go to English edition

FYI: Deutsche Edition verfügbar

Hallo mein Freund, du befindest dich auf der Englischen Edition der Startbase und laut deinem Browser sprichst du eigentlich auch Deutsch. Magst du die Sprache wechseln?

Deutsche Edition öffnen

Similar posts